Nature Communications (Sep 2017)
Predictors of responses to immune checkpoint blockade in advanced melanoma
- N. Jacquelot,
- M. P. Roberti,
- D. P. Enot,
- S. Rusakiewicz,
- N. Ternès,
- S. Jegou,
- D. M. Woods,
- A. L. Sodré,
- M. Hansen,
- Y. Meirow,
- M. Sade-Feldman,
- A. Burra,
- S. S. Kwek,
- C. Flament,
- M. Messaoudene,
- C. P. M. Duong,
- L. Chen,
- B. S. Kwon,
- A. C. Anderson,
- V. K. Kuchroo,
- B. Weide,
- F. Aubin,
- C. Borg,
- S. Dalle,
- O. Beatrix,
- M. Ayyoub,
- B. Balme,
- G. Tomasic,
- A. M. Di Giacomo,
- M. Maio,
- D. Schadendorf,
- I. Melero,
- B. Dréno,
- A. Khammari,
- R. Dummer,
- M. Levesque,
- Y. Koguchi,
- L. Fong,
- M. Lotem,
- M. Baniyash,
- H. Schmidt,
- I. M. Svane,
- G. Kroemer,
- A. Marabelle,
- S. Michiels,
- A. Cavalcanti,
- M. J. Smyth,
- J. S. Weber,
- A. M. Eggermont,
- L. Zitvogel
Affiliations
- N. Jacquelot
- INSERM U1015, Gustave Roussy Cancer Campus
- M. P. Roberti
- INSERM U1015, Gustave Roussy Cancer Campus
- D. P. Enot
- Gustave Roussy Cancer Campus
- S. Rusakiewicz
- INSERM U1015, Gustave Roussy Cancer Campus
- N. Ternès
- University Paris-Saclay
- S. Jegou
- Saint Antoine Hospital
- D. M. Woods
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center
- A. L. Sodré
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center
- M. Hansen
- Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital
- Y. Meirow
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School
- M. Sade-Feldman
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School
- A. Burra
- Division of Hematology/Oncology, Department of Medicine, University of California
- S. S. Kwek
- Division of Hematology/Oncology, Department of Medicine, University of California
- C. Flament
- INSERM U1015, Gustave Roussy Cancer Campus
- M. Messaoudene
- INSERM U1015, Gustave Roussy Cancer Campus
- C. P. M. Duong
- INSERM U1015, Gustave Roussy Cancer Campus
- L. Chen
- Department of Immunobiology, Yale School of Medicine
- B. S. Kwon
- Eutilex
- A. C. Anderson
- Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School
- V. K. Kuchroo
- Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School
- B. Weide
- Department of Dermatology, University Medical Center Tübingen
- F. Aubin
- Université de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU)
- C. Borg
- Department of Medical Oncology, University Hospital of Besancon
- S. Dalle
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1
- O. Beatrix
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1
- M. Ayyoub
- INSERM U1015, Gustave Roussy Cancer Campus
- B. Balme
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1
- G. Tomasic
- Gustave Roussy Cancer Campus
- A. M. Di Giacomo
- Medical Oncology and Immunotherapy Division, University Hospital of Siena
- M. Maio
- Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori
- D. Schadendorf
- Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ)
- I. Melero
- Division of Gene Therapy and Hepatology, Centre for Applied Medical Research
- B. Dréno
- Department of Onco-dermatology, CIC Biotherapy
- A. Khammari
- Department of Onco-dermatology, CIC Biotherapy
- R. Dummer
- Department of Dermatology, University Hospital Zürich and University of Zürich
- M. Levesque
- Department of Dermatology, University Hospital Zürich and University of Zürich
- Y. Koguchi
- Earle A. Chiles Research Institute, Providence Cancer Center
- L. Fong
- Division of Hematology/Oncology, Department of Medicine, University of California
- M. Lotem
- Sharett Institute of Oncology, Hadassah Medical Organization
- M. Baniyash
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School
- H. Schmidt
- Department of Oncology, Aarhus University Hospital
- I. M. Svane
- Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital
- G. Kroemer
- Gustave Roussy Cancer Campus
- A. Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus
- S. Michiels
- Gustave Roussy Cancer Campus
- A. Cavalcanti
- Gustave Roussy Cancer Campus
- M. J. Smyth
- Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute
- J. S. Weber
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center
- A. M. Eggermont
- Gustave Roussy Cancer Campus
- L. Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus
- DOI
- https://doi.org/10.1038/s41467-017-00608-2
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 13
Abstract
The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.
